The ambitions include at least five Phase 3 programmes in obesity and diabetes and at least five in other therapy areas, counting both new and current programmes. Novo targets a 2026–30 revenue CAGR in line with industry peers, without giving a figure. It names 14 peers, including Eli Lilly, AstraZeneca, Novartis and Roche. It also aims to scale capacity to serve ten times more people with obesity on oral GLP-1, and to maintain a broadly stable operating margin and an attractive dividend per share.

The company stresses that all ambitions run to 2030 from a 2026 baseline. It says they are inherently uncertain, do not constitute financial guidance, and that the revenue and margin ambitions are based on adjusted metrics. The DKK 150 billion pipeline figure is risk-adjusted and includes current pipeline assets.

Management presentations on Monday cover corporate and R&D strategy, therapy-area positioning, commercial strategy in the US and international markets, manufacturing and supply, and financials. The sessions are webcast, with presentation material posted on novonordisk.com.